CVRx Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $14.8 million, up 20% year-over-year.

U.S. Revenue: $13.7 million, reflecting a 22% increase.

Revenue Units in U.S.: 429 units, compared to 359 units in Q1 2025.

Gross Profit: $12.9 million, a 25% increase; gross margin improved to 87% from 84%.

R&D Expenses: Increased by 23% to $3.1 million.

SG&A Expenses: Rose by 3% to $22 million.

Net Loss: $13.1 million ($0.50 per share), improved from a net loss of $13.8 million ($0.53 per share) in Q1 2025.

Cash and Cash Equivalents: $72.3 million.

Net Cash Used in Operating and Investing Activities: $12.3 million, down from $12.9 million in Q1 2025.

2Strategic Updates and Business Highlights

Sales Organization: Strengthened with a broader and more experienced team, contributing to revenue growth.

Market Expansion: Increased active implanting centers to 257 from 252 at year-end 2025, with 56 sales territories in the U.S.

Reimbursement Initiatives: Transition to Category I CPT codes has positively impacted prior authorization approval rates, which improved to 46% in Q1 2026 from 31% in 2024.

Clinical Trials: Initiated the BENEFIT-HF trial, which aims to expand the market opportunity for Barostim therapy significantly.

3Forward Guidance and Outlook

Full-Year 2026 Revenue Guidance: Expected between $63 million and $67 million.

Q2 2026 Revenue Guidance: Anticipated between $15.1 million and $16.1 million.

Gross Margin Expectation: Projected between 85% and 87% for the full year.

Operating Expenses: Expected to be between $103 million and $107 million.

4Bad News, Challenges, or Points of Concern

Prior Authorization Challenges: A decline in approval rates was observed in March due to new Medicare Advantage regulations, leading to initial denials based on administrative issues rather than clinical rationale.

European Revenue Decline: Revenue in Europe decreased by 2%, indicating potential challenges in that market.

Net Loss: Despite improvements, the company continues to operate at a loss, raising concerns about long-term profitability.

5Notable Q&A Insights

Prior Authorization Dynamics: Management expressed confidence in overcoming recent challenges with prior authorizations, noting a healthy overturn rate for initial denials.

BENEFIT-HF Trial: The trial is seen as a significant engagement tool for new centers and is expected to enhance awareness and adoption of Barostim therapy.

Center Additions: While the expectation for new center additions remains at high single digits per quarter, variability is anticipated, with Q1 showing a lower-than-expected increase.

Medicare Advantage Mix: The patient population is split evenly between traditional Medicare and Medicare Advantage, with ongoing efforts to improve approval rates. Overall, CVRx reported a strong start to 2026, with significant revenue growth and strategic advancements, but faces ongoing challenges related to prior authorizations and market dynamics.